Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Biotheus of Guangdong Has $140 Million to Develop 8 Candidates

publication date: Oct 31, 2018

Biotheus of Guangdong raised $26 million in a new funding round to add to its $114 million in promised backing. Within five years, the company plans to build a portfolio of eight biopharma candidates, including six innovative drugs from its own discovery efforts and two other molecules. In July, Biotheus set up a research facility in the High-tech Zone of Guangdong Province's Zhuhai City. The investors included an unnamed Zhuhai government-owned investment firm, Highlight Capital (a China healthcare focused firm), and Zhuhai Huajin Assets. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital